Getting the most therapeutic potential out of cells
Peer-Reviewed Publication
A simple change in the way donor cells are processed can maximize a single cell’s production of extracellular vesicles, which are small nanoparticles naturally secreted by cells, according to new research.
A computational tool allows researchers to precisely predict locations on the surfaces of human and COVID-19 viral proteins that bind with each other, a breakthrough that will greatly benefit our understanding of the virus and the development of drugs that block binding sites.
Referrals from primary care providers (PCPs) to Pediatric Mental Health Care Access (PMHCA) programs increased and involved more complex mental health concerns, particularly regarding mood and anxiety, during the pandemic, according to a new study published online today in Psychiatric Services. These trends underscore the importance of these programs to supporting the growing need for children’s mental health care.
The rate of cervical cancer among women living in neighborhoods with the lowest socioeconomic indices is nearly two times higher than the rate among those who live in areas with the highest indices.
Kaiser Permanente research in Southern California published Nov. 25, 2021, in The Lancet Regional Health – Americas confirmed high Moderna COVID-19 vaccine effectiveness up to 5 months after the second dose. Effectiveness was 87% against COVID-19 infection, 96% against COVID-19 hospitalization, and 98% against COVID-19 death.
A recent study in mice conducted by the Monash Biomedicine Discovery Institute (BDI), has uncovered that during chronic viral infection, a protein called BMI-1 gets turned on too early in B cells and messes up the delicate balance of gene expression, resulting in antibodies that are unsuccessful in their endeavour to clear the virus from the body.
Cancer biologist Yibin Kang has spent more than 15 years investigating a little-known but deadly gene called MTDH, or metadherin, which enables cancer in two vital ways — and which he can now disable, in mice and in human tissue, with a targeted experimental treatment that will be ready for human trials in a few years. His work appears in two papers in today’s issue of Nature Cancer.